Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

Breast Cancer Research and Treatment
R WuerstleinWSG-PRIMe investigators in Germany, Austria, Switzerland

Abstract

The WSG-PRIMe Study prospectively evaluated the impact of the 70-gene signature MammaPrint® (MP) and the 80-gene molecular subtyping assay BluePrint® on clinical therapy decisions in luminal early breast cancer. 452 hormone receptor (HR)-positive and HER2-negative patients were recruited (N0, N1). Physicians provided initial therapy recommendations based on clinicopathological factors. After prospective risk classification by MammaPrint/BluePrint was revealed, post-test treatment recommendations and actual treatment were recorded. Decisional Conflict and anxiety were measured by questionnaires. Post-test switch (in chemotherapy (CT) recommendation) occurred in 29.1% of cases. Overall, physician adherence to MP risk assessment was 92.3% for low-risk and 94.3% for high-risk MP scores. Adherence was remarkably high in "discordant" groups: 74.7% of physicians initially recommending CT switched to CT omission following low-risk MP scores; conversely, 88.9% of physicians initially recommending CT omission switched to CT recommendations following high-risk MP scores. Most patients (99.2%) recommended to forgo CT post-test and 21.3% of patients with post-test CT recommendations did not undergo CT; among MP low-risk patients with pre-te...Continue Reading

References

Jan 1, 1995·Medical Decision Making : an International Journal of the Society for Medical Decision Making·A M O'Connor
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Sep 7, 2006·Journal of the National Cancer Institute·Marc BuyseUNKNOWN TRANSBIG Consortium
Apr 4, 2008·Nature·Laura J van't Veer, René Bernards
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ben S WittnerSridhar Ramaswamy
Sep 27, 2008·Breast Cancer Research and Treatment·J M Bueno-de-MesquitaM J van de Vijver
Oct 15, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S MookL J van 't Veer
Jan 30, 2010·Japanese Journal of Clinical Oncology·Makoto IshitobiKikuya Kato
Aug 5, 2011·Breast Cancer Research and Treatment·Oscar KrijgsmanAnnuska M Glas
Feb 2, 2013·International Journal of Cancer. Journal International Du Cancer·C A DrukkerS C Linn
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Apr 2, 2014·The Breast : Official Journal of the European Society of Mastology·P G CusumanoM Lutke Holzik
Jul 29, 2015·Annals of Surgical Oncology·Arjun GuptaAditya Bardia
Aug 25, 2016·The New England Journal of Medicine·Fatima CardosoUNKNOWN MINDACT Investigators
Apr 13, 2017·The Cochrane Database of Systematic Reviews·Dawn StaceyLyndal Trevena
Aug 17, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne KuijerThijs van Dalen

❮ Previous
Next ❯

Software Mentioned

MINDACT
MammaPrint
PRIMe
BluePrint
WSG

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.